{
  "nctId": "NCT01669798",
  "briefTitle": "BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",
  "officialTitle": "Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma",
  "protocolDocument": {
    "nctId": "NCT01669798",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-08-16",
    "uploadDate": "2018-08-27T14:59",
    "size": 1428219,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01669798/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 32,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2013-02",
    "completionDate": "2018-02",
    "primaryCompletionDate": "2017-09-10",
    "firstSubmitDate": "2012-07-10",
    "firstPostDate": "2012-08-21"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma w/ histologic documentation of the original primary tumor via the pathology report:\n\n  * serious, endometrioid, mucinous, or clear cell adenocarcinoma\n  * undifferentiated, mixed epithelial or transitional cell carcinoma\n  * Brenner's Tumor\n  * adenocarcinoma NOS\n* Had treatment-free interval following response to bevacizumab (CR, PR, or SD) of \\< 6 months, or have progressed during treatment w/ a bevacizumab-containing therapy\n* Measurable or detectable disease. Measurable is defined by RECIST 1.1. Each lesion must be ≥ 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or ≥ 20 mm when measured by chest x-ray. Lymph nodes must be \\> 15 mm in short axis when measured by CT or MRI. Detectable defined as no measurable disease but either ascities/pleural effusion or solid/cystic abnormalities that don't meet RECIST 1.1 - both within the setting of CA125 \\>2xULN\n* Those with measurable disease must have at least one \"target lesion\" to assess response as defined by RECIST 1.1. Tumors in a previously irradiated field will be designated as \"non-target\" lesions\n* Must have a ECOG Performance Status of 0 or 1\n* Free of active infection requiring antibiotics. Exception: uncomplicated UTI\n* Recovery from effects of recent surgery, radiotherapy, or chemotherapy\n\n  * Hormonal therapy directed at the malignant tumor must be d/c at least a week prior to registration. Hormone replacement therapy is permitted\n  * Other prior therapy directed at malignant tumor, including immunologic agents, must be d/c at least 3 weeks prior to registration; 4 weeks if prior therapy was w/ bevacizumab\n* Prior therapy\n\n  * must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. This initial treatment may have included intraperitoneal therapy, high-dose therapy, consolidation, non-cytotoxic agents or extended therapy administered after surgical or non-surgical assessment.\n  * Allowed, to receive, but not required to receive, 2 additional cytotoxic regimens for management of recurrent or persistent disease according to the following:\n\n    * Patients who have received only one prior cytotoxic regimen (platinum-based regimen for management of primary disease), must have a platinum-free interval of less than 12 months, or have progressed during platinum-based therapy, or have persistent disease after a platinum-based therapy.\n    * Patients must NOT have received any non-cytotoxic therapy for management of recurrent or persistent disease other than bevacizumab. Patients are allowed to receive, but are not required to receive, biologic (non-cytotoxic) therapy as part of their primary treatment regimen.\n* Must have adequate:\n\n  * Bone marrow function: Absolute neutrophil count (ANC) ≥ 1,500/mcl, equivalent to (CTCAE v4.0) grade 1. Platelets ≥ 100,000/mcl. Hemoglobin (Hb) ≥ 9.0 g/dL\n  * Renal function: creatinine ≤ 1.5 x upper limit of normal (ULN)\n  * Hepatic function: Bilirubin should be w/in normal limits (CTCAE v4.0, grade 1). ALT/AST, should be ≤ 1.5 x ULN (CTCAE v4.0, grade 1). For patients w/ liver metastases, ALT/AST should be ≤ 2.5 x ULN; Alkaline phosphatase should be ≤ 2.5 x ULN (CTCAE v4.0, grade 1)\n  * Neurologic function: Neuropathy ≤ CTCAE v4.0, grade 1\n* Blood coagulation parameters: PT w/ international normalized ratio (INR) \\< 1.5 x ULN \\& a PTT \\< 1.5 x ULN (or an in-range PTT if on a stable dose of therapeutic heparin). Low molecular weight heparin (enoxaparin or alternative anticoagulants (other than warfarin)) are acceptable.\n* Signed informed consent \\& authorization permitting release of personal health information\n* Negative serum pregnancy test if of childbearing potential prior to study entry \\& use of effective form of contraception until 3 months after receiving last drug treatment\n* Patients may have undergone a major or minor surgical procedure as long as:\n\n  * \\> 28 days prior to the first date of study therapy\n  * Core biopsy or IV Port placement greater than 7 days prior to the first date of study therapy\n\nExclusion Criteria:\n\n* Previous treatment w/ BIBF 1120.\n* Pregnant or breastfeeding.\n* Received radiation to more than 25% of marrow-bearing areas\n* History of other invasive malignancies, w/ the exception of non-melanoma skin cancer, if there is any evidence of other malignancy being present w/in the last five years.\n* Received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for treatment of ovarian, fallopian tube, or primary peritoneal cancer w/in the last 5 years.\n* Prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer or localized breast cancer w/in the last 5 years.\n* A history of abdominal or tracheal-esophageal fistula, or gastrointestinal perforation\n* A history of intra-abdominal abcess w/in 6 months of enrollment\n* Serious, uncontrolled, concomitant disorder(s) such as diabetes mellitus\n* Patients w/ clinically significant cardiovascular disease including: uncontrolled hypertension: systolic \\> 150 mm Hg/diastolic \\> 90 mm Hg; unstable angina or who have had a myocardial infarction w/in the past six months prior to registration; congestive heart failure; cardiac arrhythmia requiring medication (doesn't include asymptomatic atrial fibrillation); grade 2 or greater peripheral vascular disease (at least brief (\\<24 hours) episodes of ischemia managed non-surgically \\& w/o permanent deficit.\n* Serious non-healing wound, ulcer, or bone factor.\n\n  o Granulating incisions healing by secondary intention w/ no evidence of fascial dehiscence or infection ARE eligible but require weekly wound examinations.\n* Active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels.\n* History/evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled w/ standard medical therapy, any brain metastases, CVA, TIA, or subarachnoid hemorrhage w/in 6 months of the first date of treatment on this study.\n* Central pulmonary metastases/recent hemoptysis (≥1/2 tsp of red blood) w/in 28 days of registration.\n\n  * Clinically significant proteinuria (i.e. \\>Grade 1) or UPC ratio above 1.0\n  * Suspicion of transmural tumor bowel involvement based on the investigator's discretion.\n* Clinical symptoms/signs of gastrointestinal obstruction \\& require IV hydration \\&/or nutrition.\n* Patients taking warfarin are not eligible",
    "healthyVolunteers": false,
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Patients Who Survive Progression-free",
        "description": "Measure of Progression Free Survival (PFS) by the percentage of patients who survive progression-free for at least 6 months after initiating study therapy in patients with bevacizumab-resistant, persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.",
        "timeFrame": "6 months"
      }
    ],
    "secondary": [
      {
        "measure": "Objective Tumor Response Via RECIST (Response Evaluation Criteria in Solid Tumors) 1.1",
        "description": "Evaluating the percentage of patients who have objective tumor response (complete or partial) based on RECIST 1.1 criteria.",
        "timeFrame": "1 year"
      },
      {
        "measure": "Duration of Progression-Free Survival",
        "description": "The duration of progression-free survival and overall survival measured in months; Progression-Free Survival (PFS) is defined as the duration of time from study entry to time of progression or death, whichever occurs first.",
        "timeFrame": "Through study completion, on average 2 years"
      },
      {
        "measure": "Objective Tumor Response Based on GCIG CA-125 Criteria",
        "description": "The proportion of patients who have objective tumor response (complete or partial) based on Gynaecologic Cancer InterGroup(GCIG) CA-125 criteria which is: \"A response according to CA 125 has occurred if there is at least a 50% reduction in CA 125 levels from a pretreatment sample. The response must be confirmed and maintained for at least 28 days.\".",
        "timeFrame": "1 year"
      },
      {
        "measure": "Adverse Event Frequency and Severity",
        "description": "To determine frequency and severity of adverse events as assessed using NCI Common Toxicity Criteria version 4.",
        "timeFrame": "1 year"
      }
    ],
    "other": [
      {
        "measure": "Concentration of Select Growth Factors Reported Measured in Picograms Per Milliliter as a Function of Treatment Response",
        "description": "Correlating baseline and on treatment levels of additional growth factors measured in picograms per milliliter that may be co- or counter- regulated with VEGF with response to treatment",
        "timeFrame": "1 year"
      },
      {
        "measure": "Coagulation and Endothelial Cell Activation Markers",
        "description": "To measure baseline and on treatment levels of additional growth factors that may be co- or counter- regulated with VEGF and correlate with response to treatment.",
        "timeFrame": "1 year"
      },
      {
        "measure": "VEGF Levels Correlated With Treatment Outcome",
        "description": "Baseline levels of VEGF were correlated with treatment outcome. Results are stratified in groups: \"Partial Response (PR) or Stable Disease (SD)\" and \"Progressive Disease (PD)\"",
        "timeFrame": "1 year"
      },
      {
        "measure": "Concentration of Select Growth Factors Measured in Nanograms Per Milliliter Reported as a Function of Treatment Response",
        "description": "Correlating baseline and on treatment levels of additional growth factors measured in nanograms per milliliter that may be co- or counter- regulated with VEGF with response to treatment",
        "timeFrame": "1 year"
      },
      {
        "measure": "Concentration of VCAM-1 Reported as a Function of Treatment Response",
        "description": "Correlating baseline and on treatment levels of VCAM-1 measured in micrograms per milliliter that may be co- or counter- regulated with VEGF with response to treatment",
        "timeFrame": "1 year"
      }
    ]
  },
  "realComplexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 30,
      "exclusionCount": 18,
      "totalCount": 48
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 4,
      "otherCount": 5,
      "totalCount": 10
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-21T22:32:07.374Z",
  "dataSource": "ClinicalTrials.gov API v2"
}